Advertisement

 

 

Addressing Antiretroviral Therapy-Associated Drug-Drug Interactions in Patients Requiring Treatment for Opportunistic Infections in Low-Income and Resource-Limited Settings.

Addressing Antiretroviral Therapy-Associated Drug-Drug Interactions in Patients Requiring Treatment for Opportunistic Infections in Low-Income and Resource-Limited Settings.
Author Information (click to view)

Chastain DB, Franco-Paredes C, Stover KR,


Chastain DB, Franco-Paredes C, Stover KR, (click to view)

Chastain DB, Franco-Paredes C, Stover KR,

Advertisement
Share on FacebookTweet about this on TwitterShare on LinkedIn

Journal of clinical pharmacology 2017 09 08() doi 10.1002/jcph.978

Abstract

An increasing number of human immunodeficiency virus (HIV)-infected patients are achieving virologic suppression on antiretroviral therapy (ART) limiting the use of primary and secondary antimicrobial prophylaxis. However, in low-income and resource-limited settings, half of those infected with HIV are unaware of their diagnosis, and fewer than 50% of patients on ART achieve virologic suppression. Management of comorbidities and opportunistic infections among patients on ART may lead to inevitable drug-drug interactions (DDIs) and even toxicities. Elderly patients, individuals with multiple comorbidities, those receiving complex ART, and patients living in low-income settings experience higher rates of DDIs. Management of these cytochrome P450-mediated, nonmediated, and drug transport system DDIs is critical in HIV-infected patients, particularly those in resource-limited settings with few options for ART. This article critically analyzes and provides recommendations to manage significant DDIs and drug toxicities in HIV-infected patients receiving ART.

Submit a Comment

Your email address will not be published. Required fields are marked *

3 − two =

[ HIDE/SHOW ]